Apoptosis enzyme-linked immunosorbent assay distinguishes anticancer drugs from toxic chemicals and predicts drug synergism

被引:17
作者
Frankfurt, OS
Krishan, A
机构
[1] Univ Miami, Sch Med, Dept Radiat Oncol, Div Expt Therapeut, Miami, FL 33136 USA
[2] Apostain Inc, Miami, FL 33154 USA
关键词
enzyme-linked-immunosorbent assay; monoclonal antibody; apoptosis; anticancer drugs; drug screening; chemosensitivity assay;
D O I
10.1016/S0009-2797(02)00241-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The effects of anticancer drugs and toxic compounds on leukemic cells in culture were evaluated by enzyme-linked-immunosorbent. assay (ELISA) based on the detection of apoptotic cells by a monoclonal antibody against singlestranded DNA. The concentrations of 13 anticancer drugs, which increased apoptosis ELISA absorbance, were similar to the concentrations decreasing long-term cell survival. Short-term metabolic tetrazolium-based 3-(4,5-dimethylthiazol-yl)-2,5-diphenyformazan bromide (MTT) assay was significantly less sensitive than apoptosis ELISA and the cell survival assay. In contrast to anticancer drugs, 12 toxic chemicals did not increase apoptosis ELISA absorbance at cytotoxic concentrations. The difference between two groups of compounds by apoptosis ELISA was especially large in cultures treated with twofold of concentrations producing 50% inhibition of cell growth: all anticancer drugs induced intense reaction (mean absorbance 2.0), while none of the toxic chemicals induced apoptosis. The application of apoptosis ELISA to chemosensitivity testing was evaluated by its ability to detect synergism of anticancer drug combinations. Among 66 drug combinations tested, only combination of nitrogen mustard with mithramycin was highly synergistic by the apoptosis ELISA, as defined by apoptosis induction with the combination containing each drug at 50% of effective concentration. This combination was also synergistic in the cell survival assay, producing significant cell kill while each drug alone had no effect on cell survival. This synergism was not detected by MTT assay. We conclude that apoptosis ELISA could be useful for drug development and chemosensitivity assessment as it can distinguish clinically useful anticancer drugs from toxic compounds, is as sensitive as the long-term cell survival assay and can detect anticancer drug synergism by rapid evaluation of apoptosis induction. (C) 2002 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:89 / 99
页数:11
相关论文
共 31 条
[1]
Aldridge DR, 1998, CANCER RES, V58, P2817
[2]
ALLEY MC, 1988, CANCER RES, V48, P589
[3]
Amundson SA, 2000, CANCER RES, V60, P6101
[4]
Brown JM, 1999, CANCER RES, V59, P1391
[5]
CARMICHAEL J, 1987, CANCER RES, V47, P936
[6]
Caserini C, 1997, CLIN CANCER RES, V3, P955
[7]
Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential [J].
Evans, SM ;
Casartelli, A ;
Herreros, E ;
Minnick, DT ;
Day, C ;
George, E ;
Westmoreland, C .
TOXICOLOGY IN VITRO, 2001, 15 (4-5) :579-584
[8]
Frankfurt OS, 1997, CLIN CANCER RES, V3, P465
[9]
PLEIOTROPIC DRUG-RESISTANCE AND SURVIVAL ADVANTAGE IN LEUKEMIC-CELLS WITH DIMINISHED APOPTOTIC RESPONSE [J].
FRANKFURT, OS ;
SECKINGER, D ;
SUGARBAKER, EV .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (02) :217-224
[10]
Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. [J].
Frankfurt, OS ;
Krishan, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 253 (1-2) :133-144